{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:29:33Z","timestamp":1793233773698,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"Supplement_I","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Atherosclerotic cardiovascular disease is a systemic condition involving several vascular districts. The most involved vascular bed, beyond the coronary district, is represented by the peripheral arteries, whose involvement can give rise to cerebrovascular or peripheral events. PCSK9 inhibitors (PCSK9i) have established themselves as safe and effective drugs in reducing cholesterol linked to low-density lipoprotein (LDL-C), a causative factor of disease, with a consequent reduction in cardiovascular events. The two main studies on anti-PCSK9 antibodies, the FOURIER study for evolocumab and the ODYSSEY OUTCOMES study for alirocumab, highlighted the effectiveness in reducing LDL-C levels and its translation in a lower event rate of around 15%. Sub-analysis of these two trials showed how PCSK9i prevent cerebrovascular and\/or peripheral events and how patients with already known cerebrovascular or peripheral disease benefit more from the action of these drugs than patients who do not have a widespread disease. Current evidence suggests that the preventive action of cerebrovascular and peripheral events is mainly expressed through reducing LDL-C levels. Although there are data regarding the association of PCSK9 levels and inflammatory status, propensity for thrombosis and platelet aggregation, these are currently less robust and do not justify a cardiovascular event reduction action that is independent of the action on LDL-C.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suac099","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T15:20:16Z","timestamp":1668266416000},"page":"I34-I37","source":"Crossref","is-referenced-by-count":5,"title":["Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?"],"prefix":"10.1093","volume":"24","author":[{"given":"Arturo","family":"Cesaro","sequence":"first","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples"},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant\u2019Anna and San Sebastiano\u2019 , Caserta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Acerbo","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples"},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant\u2019Anna and San Sebastiano\u2019 , Caserta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Raucci","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples"},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant\u2019Anna and San Sebastiano\u2019 , Caserta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5018-830X","authenticated-orcid":false,"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Campania \u2018Luigi Vanvitelli\u2019 , Naples"},{"name":"Division of Cardiology, A.O.R.N. \u2018Sant\u2019Anna and San Sebastiano\u2019 , Caserta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"2022111417522472300_suac099-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022111417522472300_suac099-B2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022111417522472300_suac099-B3","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022111417522472300_suac099-B4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hfc.2021.07.008","article-title":"New frontiers in the treatment of homozygous familial hypercholesterolemia","volume":"18","author":"Cesaro","year":"2022","journal-title":"Heart Fail Clin"},{"key":"2022111417522472300_suac099-B5","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3390\/jcm10071510","article-title":"Inhibitors of protein convertase subtilisin\/kexin 9 (PCSK9) and acute coronary syndrome (ACS): the state-of-the-art","volume":"10","author":"Iannuzzo","year":"2021","journal-title":"J Clin Med"},{"key":"2022111417522472300_suac099-B6","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"2022111417522472300_suac099-B7","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022111417522472300_suac099-B8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"2022111417522472300_suac099-B9","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","article-title":"Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis","volume":"51","author":"Giugliano","year":"2020","journal-title":"Stroke"},{"key":"2022111417522472300_suac099-B10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40200-020-00557-6","article-title":"Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials","volume":"19","author":"Cordero","year":"2020","journal-title":"J Diabetes Metab Disord"},{"key":"2022111417522472300_suac099-B11","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.numecd.2021.03.026","article-title":"The effect of PCSK9 inhibitors on brain stroke prevention: a systematic review and meta-analysis","volume":"31","author":"Qin","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2022111417522472300_suac099-B12","doi-asserted-by":"crossref","first-page":"106057","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.106057","article-title":"Efficacy and safety of PCSK9 inhibitors in stroke prevention","volume":"30","author":"Moustafa","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2022111417522472300_suac099-B13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2022111417522472300_suac099-B14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"2022111417522472300_suac099-B15","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1093\/eurheartj\/ehab604","article-title":"Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial","volume":"42","author":"Oyama","year":"2021","journal-title":"Eur Heart J"},{"key":"2022111417522472300_suac099-B16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2019.07.002","article-title":"Interaction between serum endotoxemia and proprotein convertase subtilisin\/kexin 9 (PCSK9) in patients with atrial fibrillation: a post-hoc analysis from the ATHERO-AF cohort","volume":"289","author":"Pastori","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022111417522472300_suac099-B17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022111417522472300_suac099-B18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/eurheartj\/ehv637","article-title":"Prognostic value of PCSK9 levels in patients with acute coronary syndromes","volume":"37","author":"Gencer","year":"2016","journal-title":"Eur Heart J"},{"key":"2022111417522472300_suac099-B19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). genetics, mutations, expression, and perspective for long-term inhibition","volume":"46","author":"Cesaro","year":"2020","journal-title":"BioFactors"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_I\/I34\/47030454\/suac099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_I\/I34\/47030454\/suac099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:56:00Z","timestamp":1668448560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/24\/Supplement_I\/I34\/6823845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":19,"journal-issue":{"issue":"Supplement_I","published-online":{"date-parts":[[2022,11,12]]},"published-print":{"date-parts":[[2022,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac099","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,12]]},"published":{"date-parts":[[2022,11,12]]}}}